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A number of GP factors interacted with patient predictors to get
Zostavax.
Conclusion: There is a high degree of awareness of the impact
of shingles and reasonable likelihood of vaccine uptake. GP recom-
mendation is likely to be the key inﬂuence on patients getting the
zoster vaccine.
Strategies to enhance GP recommendation of the Zostavax will
have a strong inﬂuence on Zostavax uptake
http://dx.doi.org/10.1016/j.ijid.2014.03.1320
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measurable up to 38 years after vaccination
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Background: In May 2013, the WHO sage announced a yel-
low fever vaccination policy change stating that revaccination of
healthy individuals every 10 years was no longer necessary. In our
opinion, this statementwas based on scarce research andwe there-
fore sought for a more solid base of evidence for this guideline.
The aim of this study is to assess antibody presence and yellow
fever (YF)-speciﬁc T cell responses in healthy individuals vacci-
nated more than 10 years ago.
Methods & Materials: From January 2012 to November 2013,
75 healthy individuals vaccinated more than 10 years ago and 30
individuals vaccinated less than 10 years ago were included in this
study. Virus neutralizing antibodies were studied using a Plaque
ReductionNeutralization Test. Thepresence andphenotypic proﬁle
of YF-speciﬁc CD8+T cells was characterised by tetramer staining.
YF-speciﬁc CD8+T cell responses were assessed after stimulation
with tetramer speciﬁc peptides.
Results: Neutralizing antibodies and YF speciﬁc CD8+T cells
were present in comparable percentages of long-term (up to
38 years after vaccination) and short-term vaccinees. In two
HLA A2+vaccinees vaccinated 12 and 15 years ago, (0.6-3.0%
of CD8+T cells) were identiﬁed and shown to have both
classical (CD45RAdimCD27+ ) and effector memory phenotypes
(CD45RAhiCD27). In one HLA B27+ individual vaccinated 28 years
ago, yellow fever speciﬁc T cells were identiﬁed after peptide stim-
ulation.
Conclusion: Antibodies were present up to 38 years following
vaccination. Functional YF-speciﬁc T cells with various phenotypes
were present up to 28 years after vaccination. The 17D yellow
fever vaccine induces a long term humoral and cellular immune
response, and our results provide a more solid base of evidence for
the WHO guideline change.
http://dx.doi.org/10.1016/j.ijid.2014.03.1321
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Background: Most meningococcal disease in Africa is caused
by serogroups A and W of N. meningitidis. Recently, new cases
of meningitis caused by N. meningitidis serogroup X have been
reported in countries from“meningitis belt”. Novaccines havebeen
developed against this serogroup. The aim of this work is to show
the different R&D strategies under evaluation at Finlay Institute
against the pathogen.
Methods & Materials: Experimental lots of outer membrane
vesicles (OMVx)were obtained bydeoxycholate extractionmethod
from N. meningitidis serogroup X BuFa 2/97 strain. Physico-
chemical characterization was carried out to determine the size,
morphology and the main antigens in vesicles. Secondly, capsu-
lar polysaccharide X (PsX) was obtained by phenol free process
and characterized by HPLC, HPAEC-PAD and other analytical tech-
niques. A combined formulation of OMVx plus PsX adsorbed to
aluminum hydroxide (OMVx/AL) was developed and evaluated in
mice models. Finally, conjugates of PsX to diphteria or tetanus tox-
oid were obtained. The antigen speciﬁc IgG responses induced by
these formulations to polysaccharides or OMVx were evaluated by
ELISA, and serum bactericidal assay (SBA).
Results: OMVx size was between 90-120nm and OpcA, PorA
and RmpM protein were identiﬁed. Lots from PsX were obtained
by high scale process (100 L). PsX size was estimated in 500g/mol L
and Kd in 0.5.OMVx/Al induced high speciﬁc anti-OMVx antibod-
ies response in sera with bactericidal activity. OMVx with PsX also
contributes to increase SBA in the group of mice immunized with
this formulation aswell as the induction of anti PsX antibodies. PsX
conjugates also induced high speciﬁc titers and SBA.
Conclusion: Puriﬁcation of capsular polysaccharide, combi-
nation of OMVx with the PsX as well as the formulation of
multivalent OMV vaccines or conjugates from different meningo-
coccal serogroups is the focus of our current work.
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